Rickets

1. Clinical Overview

Summary

Rickets is a metabolic bone disease characterized by defective mineralization of the growth plate (physis) occurring in children before epiphyseal closure. It results from inadequate availability of calcium and/or phosphate for bone mineralization, most commonly due to vitamin D deficiency. [1,2] The condition represents a failure of endochondral ossification, leading to accumulation of unmineralized cartilage matrix at the growth plate with resultant skeletal deformities, growth impairment, and potentially life-threatening complications. [3]

While nutritional rickets (vitamin D deficiency) accounts for the majority of cases globally, clinicians must recognize genetic and metabolic forms including hypophosphataemic rickets, vitamin D-dependent rickets, and renal osteodystrophy. [4,5]

Key Facts

Clinical Pearls

• Rachitic Rosary: Palpable beading at costochondral junctions - pathognomonic for rickets
• Craniotabes: Soft skull bones with "ping-pong ball" sensation on palpation - occurs in infancy
• Not Just Bones: Rickets affects cardiac, respiratory, immune, and neuromuscular systems
• Treat Early: Delay beyond 2-3 years leads to permanent skeletal deformities requiring surgery
• Maternal Status Matters: Neonatal rickets reflects maternal vitamin D deficiency during pregnancy [6]
• Dark Skin + Latitude: High-risk combination requiring prophylactic supplementation
• Exclusively Breastfed: Breast milk contains only 20-40 IU/L vitamin D - insufficient without supplementation [7]

---

2. Epidemiology

Global Distribution

Nutritional rickets remains a significant global health problem despite being preventable. Prevalence varies dramatically by geography, ethnicity, and socioeconomic factors. [8,9]

High-Prevalence Regions:

• Middle East: 40-70% vitamin D deficiency in children
• South Asia: 30-50% prevalence in urban areas
• Sub-Saharan Africa: Endemic in many regions
• North Africa: High rates due to limited sun exposure, covered clothing

Re-emergence in Developed Nations:

• UK: Increasing incidence in immigrant populations (South Asian, Middle Eastern, African)
• North America: Rising cases in exclusively breastfed infants without supplementation
• Northern Europe: Seasonal variation with winter/spring predominance
• Australia: Paradoxically present despite sunshine, due to sun avoidance behaviors [10]

Age Distribution

Risk Factors

Nutritional/Environmental

Maternal Factors

• Maternal vitamin D deficiency: Depleted fetal stores at birth [6]
• Maternal malabsorption: Coeliac disease, inflammatory bowel disease
• Maternal obesity: Vitamin D sequestration in adipose tissue
• Multiple pregnancy: Increased fetal demands

Malabsorption Disorders

• Coeliac disease: Small bowel villous atrophy
• Cystic fibrosis: Fat malabsorption affecting vitamin D absorption
• Crohn's disease: Ileal involvement
• Biliary atresia: Impaired bile salt secretion
• Short gut syndrome: Post-surgical malabsorption

Medications

• Anticonvulsants: Phenytoin, carbamazepine (induce hepatic CYP450)
• Glucocorticoids: Reduce calcium absorption, increase bone resorption
• Cholestyramine: Binds vitamin D in gut

Genetic Forms (Less Common)

• X-linked hypophosphataemic rickets (XLH): PHEX gene mutation
• Vitamin D-dependent rickets type 1 (VDDR1): CYP27B1 deficiency
• Vitamin D-dependent rickets type 2 (VDDR2): Vitamin D receptor mutation
• Hereditary hypophosphataemic rickets with hypercalciuria (HHRH)

---

3. Pathophysiology

Vitamin D Metabolism Pathway

SKIN (7-Dehydrocholesterol)
         + UVB (290-320 nm)
                 ↓
         Pre-vitamin D₃
                 ↓ (Heat-dependent isomerization)
         CHOLECALCIFEROL (Vitamin D₃)
                 ↓
         LIVER (25-Hydroxylase/CYP2R1)
                 ↓
      25-HYDROXYVITAMIN D [25(OH)D]
         (Calcidiol) ← STORAGE FORM ← MEASURED IN SERUM
                 ↓
         KIDNEY (1α-Hydroxylase/CYP27B1)
                 ↓ (PTH-stimulated, FGF23-suppressed)
      1,25-DIHYDROXYVITAMIN D [1,25(OH)₂D]
         (Calcitriol) ← ACTIVE HORMONE
                 ↓
      Nuclear Vitamin D Receptor (VDR)
                 ↓
         BIOLOGICAL EFFECTS:
         • Intestinal Ca²⁺/PO₄³⁻ absorption
         • Bone mineralization
         • Muscle function
         • Immune modulation

Molecular Pathophysiology of Rickets

Vitamin D Deficiency Cascade

1. Reduced Vitamin D → Decreased Intestinal Calcium Absorption

   • 1,25(OH)₂D binds nuclear VDR in enterocytes
   • Upregulates calcium transport proteins (TRPV6, calbindin-D9k, PMCA1b)
   • Deficiency → passive absorption only (~10-15% efficiency vs. 30-40% active)

2. Hypocalcaemia → Secondary Hyperparathyroidism

   • Calcium-sensing receptor (CaSR) on parathyroid cells detects low Ca²⁺
   • PTH secretion increases to restore normocalcaemia
   • PTH mobilizes calcium from bone reservoir

3. PTH-Mediated Phosphate Wasting

   • PTH acts on proximal renal tubule
   • Inhibits sodium-phosphate cotransporter (NPT2a/NPT2c)
   • Increased urinary phosphate excretion → hypophosphataemia

4. Hypophosphataemia → Defective Mineralization

   • Insufficient calcium-phosphate product for hydroxyapatite formation
   • Calcium × Phosphate product < 40 mg²/dL² → mineralization failure
   • Unmineralized osteoid accumulates at growth plate
   • Cartilage matrix not converted to bone

Growth Plate Histopathology [2]

Normal Growth Plate Zones:

• Reserve zone → Proliferative zone → Hypertrophic zone → Mineralization zone

Rachitic Growth Plate:

• Widened proliferative zone: Disordered chondrocyte columns
• Expanded hypertrophic zone: Failure of apoptosis and vascular invasion
• Absent mineralization zone: Accumulation of unmineralized cartilage matrix
• Irregular metaphyseal border: Cupping and fraying on radiographs

Phosphate Metabolism in Rickets

In hypophosphataemic rickets (e.g., XLH), the primary defect is renal phosphate wasting without secondary hyperparathyroidism:

• PHEX gene mutation → Increased FGF23 production
• FGF23 → Inhibits renal phosphate reabsorption (NPT2a/NPT2c)
• FGF23 → Suppresses 1α-hydroxylase → Low 1,25(OH)₂D despite hypophosphataemia
• Result: Low phosphate + Normal/low-normal calcium + Normal/low PTH

Calcium Homeostasis Disruption

Systemic Effects Beyond Bone

Neuromuscular

• Hypocalcaemia → Neuromuscular irritability: Tetany, carpopedal spasm, laryngospasm, seizures
• Muscle weakness: VDR expressed in skeletal muscle; deficiency impairs muscle function
• Hypotonia: Proximal muscle weakness, delayed motor milestones

Cardiac

• Dilated cardiomyopathy: Impaired myocardial calcium handling [11]
• Heart failure: Can be presenting feature in severe deficiency
• QT prolongation: Risk of arrhythmias

Respiratory

• Respiratory muscle weakness: Increased work of breathing
• Recurrent pneumonia: Impaired immune function
• Chest wall deformity: Restrictive lung disease

Immunological

• VDR expressed in immune cells: Macrophages, T-cells, B-cells
• Impaired antimicrobial peptide production: Cathelicidin, defensins
• Increased infection susceptibility: Respiratory and gastrointestinal infections [12]

---

4. Clinical Presentation

Classic Skeletal Features

Skull (Infancy: 0-12 months)

Chest Wall (6-24 months)

Limbs (Weight-bearing Age: 12 months+)

Spine

• Scoliosis: Lateral curvature from vertebral body softening
• Kyphosis: Posterior curvature, "rachitic kyphosis"
• Gibbus deformity: Sharp angular kyphosis

Dentition

• Delayed tooth eruption: Primary and permanent teeth
• Enamel hypoplasia: Defective enamel formation
• Increased dental caries: Weak enamel structure
• Dental abscesses: Increased susceptibility

Non-Skeletal Manifestations

Neurological

• Hypocalcaemic seizures: Generalized tonic-clonic; can be presenting feature
• Tetany: Carpopedal spasm, Chvostek sign, Trousseau sign
• Laryngospasm: Stridor, respiratory distress (life-threatening)
• Developmental delay: Motor milestones delayed; cognitive usually preserved
• Hypotonia: "Floppy infant" presentation
• Apnoea: Severe hypocalcaemia

Cardiac (Rare but Serious)

• Dilated cardiomyopathy: Biventricular dilatation and dysfunction [11]
• Heart failure: Tachycardia, tachypnoea, hepatomegaly, gallop rhythm
• Arrhythmias: Prolonged QT interval

Respiratory

• Recurrent lower respiratory tract infections: Impaired immunity [12]
• Respiratory failure: Muscle weakness, chest wall deformity
• Pneumonia: Increased susceptibility

Growth

• Short stature: Growth plate dysfunction impairs longitudinal growth
• Failure to thrive: Multifactorial; feeding difficulties, malabsorption if present
• Delayed puberty: In adolescent rickets

Haematological

• Anaemia: Normocytic normochromic; multifactorial
• Increased infection risk: Impaired immune function

Age-Specific Presentations

Neonatal Rickets (0-3 months)

• Maternal vitamin D deficiency during pregnancy [6]
• Craniotabes (often dismissed as normal variant)
• Hypocalcaemic seizures in first weeks of life
• Respiratory distress from hypocalcaemia/muscle weakness
• High index of suspicion needed

Infantile Rickets (3-18 months)

• Classic presentation period
• Cranial and chest wall signs prominent
• Delayed motor milestones (rolling, sitting, standing)
• Rachitic rosary, wrist/ankle widening
• Hypotonia, "frog-leg" posture

Toddler Rickets (18 months - 3 years)

• Lower limb deformities emerge with weight-bearing
• Genu varum (bow legs) most common
• Delayed walking or waddling gait
• Short stature becomes apparent
• Fractures with minimal trauma

Late Childhood Rickets (3-10 years)

• Often genetic/metabolic forms
• Bone pain, especially in lower limbs
• Genu valgum (knock knees)
• Short stature, growth failure
• Dental problems prominent

Adolescent Rickets (10-18 years)

• Bone pain, myalgia, fatigue
• Gait abnormalities
• Fractures (stress fractures in athletes)
• Delayed puberty
• Short final height

Symptom Severity Spectrum

Mild

• Biochemical abnormalities only
• Minimal/no radiological changes
• No clinical signs
• Detected on screening

Moderate

• Clinical skeletal signs present
• Rachitic rosary, wrist widening
• Radiological changes evident
• Hypotonia, delayed milestones
• No life-threatening features

Severe

• Gross skeletal deformities
• Hypocalcaemic complications (seizures, tetany)
• Cardiomyopathy, heart failure
• Respiratory compromise
• Multiple fractures
• Medical emergency

---

5. Clinical Examination

Systematic Examination Approach

General Inspection

• Growth parameters: Plot height, weight, head circumference on growth charts
• Nutritional status: Assess for signs of malnutrition, failure to thrive
• Skin pigmentation: Note dark skin (increased risk)
• General appearance: Dysmorphic features (genetic rickets), signs of systemic illness

Skull Examination (Infant)

Inspection:

• Frontal bossing (prominent forehead)
• Parietal flattening
• Head shape abnormalities

Palpation:

• Craniotabes: Gentle pressure over parietal/occipital bones → "ping-pong ball" sensation
• Fontanelle: Size, tension (delayed closure in rickets)
• Sutures: Widened, palpable ridges

Chest Examination

Inspection:

• Anteroposterior diameter (barrel chest)
• Pectus carinatum (pigeon chest) or excavatum (funnel chest)
• Asymmetry, scoliosis
• Breathing pattern (increased work of breathing)

Palpation:

• Rachitic rosary: Palpable beads along costochondral junctions (midclavicular line)
• Harrison's sulcus: Horizontal groove along lower chest

Auscultation:

• Respiratory sounds (crackles if pneumonia)
• Cardiac auscultation (tachycardia, gallop if cardiomyopathy)

Upper Limb Examination

Inspection:

• Wrist widening (compare to normal side if asymmetric)
• Forearm deformities (bowing rare)

Palpation:

• Distal radius/ulna metaphyseal expansion
• Tenderness over growth plates

Function:

• Range of motion (usually preserved)
• Grip strength

Lower Limb Examination

Inspection:

• Genu varum: Measure intercondylar distance (child supine, ankles together)
  • "Normal: < 3 cm"
  • "Mild: 3-5 cm"
  • "Moderate: 5-8 cm"
  • "Severe: 8 cm"
• Genu valgum: Measure intermalleolar distance (child supine, knees together)
  • "Normal: < 3 cm"
  • "Pathological: 3 cm after age 7 years"
• Ankle widening: Prominent distal tibia/fibula
• Foot deformities: Pes planus (flat feet)

Gait Assessment (if walking):

• Waddling gait (proximal muscle weakness)
• Limp, antalgic gait (bone pain)
• Reduced cadence, short steps

Palpation:

• Tibial/femoral bowing
• Tenderness over long bones
• Ankle metaphyseal widening

Measurement:

• Leg length discrepancy (supine, anterior superior iliac spine to medial malleolus)
• Thigh-foot angle

Spine Examination

• Inspection: Scoliosis, kyphosis, gibbus deformity
• Palpation: Spinous process alignment, paraspinal muscle tone

Neuromuscular Examination

Tone:

• Hypotonia (common in rickets)
• Assess upper and lower limbs

Power:

• Proximal muscle weakness (shoulder abduction, hip flexion)
• MRC grading

Reflexes:

• May be brisk if hypocalcaemia present
• Chvostek sign: Tap facial nerve → facial muscle twitch (hypocalcaemia)
• Trousseau sign: Inflate BP cuff above systolic × 3 min → carpopedal spasm (hypocalcaemia)

Developmental Assessment:

• Motor milestones (often delayed)
• Cognitive assessment (usually preserved)

Cardiovascular Examination

• Heart rate: Tachycardia (heart failure, anaemia)
• Heart sounds: Gallop rhythm (S3 in heart failure)
• Murmurs: Functional murmurs common; exclude structural disease
• Signs of heart failure: Hepatomegaly, peripheral oedema (rare in children)

Dental Examination

• Tooth eruption status
• Enamel hypoplasia
• Caries, abscesses

Signs of Hypocalcaemia (Emergency)

• Neuromuscular irritability: Jitteriness, tremor
• Tetany: Carpopedal spasm, muscle cramps
• Chvostek sign: Positive
• Trousseau sign: Positive
• Seizures: Generalized tonic-clonic
• Laryngospasm: Stridor, respiratory distress
• Apnoea: Especially in neonates

---

6. Investigations

Blood Tests

First-Line Biochemistry

Vitamin D Status Classification: [13]

• Severe deficiency: < 25 nmol/L (< 10 ng/mL)
• Deficiency: 25-50 nmol/L (10-20 ng/mL)
• Insufficiency: 50-75 nmol/L (20-30 ng/mL)
• Sufficiency: 75 nmol/L (30 ng/mL)

Additional Biochemistry

Haematology

• Full blood count: Anaemia (normocytic normochromic)
• Inflammatory markers (CRP, ESR): If infection suspected

Urine Tests

TRP Calculation: TRP (%) = [1 - (Urine PO₄ × Serum Creatinine) / (Serum PO₄ × Urine Creatinine)] × 100

• Normal: 85-95%
• Low (< 85%): Renal phosphate wasting

Radiology

Plain Radiographs (First-Line)

Best Sites for Diagnosis:

• Wrist (AP): Fastest-growing metaphysis in infants; earliest changes
• Knee (AP): Useful in toddlers/older children
• Chest radiograph: Incidental findings; assess for pneumonia

Classic Radiological Features: [1,2]

Radiographic Severity Grading (Thacher Score):

• Grade 0: Normal
• Grade 1: Mild metaphyseal changes
• Grade 2: Moderate cupping/fraying
• Grade 3: Severe cupping/fraying; loss of metaphyseal definition
• Grade 4: Gross metaphyseal changes; pathological fractures

Advanced Imaging

Bone Densitometry (DXA Scan):

• Quantifies bone mineral density
• Z-score < -2.0 indicates low bone mass for age
• Useful for monitoring response to treatment

99mTc-Sestamibi Scan:

• Identify ectopic parathyroid adenoma (rare)
• Not routine in rickets

MRI:

• Not routine for rickets diagnosis
• May be used for research or complex cases

Differential Diagnosis Workup

Genetic Testing

Indications:

• Persistent hypophosphataemia despite vitamin D repletion
• Family history of rickets
• Atypical biochemistry (e.g., normal 25(OH)D)
• Failure to respond to standard treatment
• Suggestive features (e.g., alopecia in VDDR2)

Genes to Consider:

• PHEX: X-linked hypophosphataemic rickets
• CYP27B1: VDDR type 1
• VDR: VDDR type 2
• FGF23, DMP1, ENPP1: Autosomal hypophosphataemic rickets
• SLC34A3: Hereditary hypophosphataemic rickets with hypercalciuria (HHRH)
• ALPL: Hypophosphasia

---

7. Management

Nutritional Rickets (Vitamin D Deficiency)

Treatment Regimens [1,13,14]

Global Consensus Recommendations (Munns et al., 2016): [1]

Alternative High-Dose Regimens (used in some countries):

• < 6 months: 50,000 IU oral once, then 400 IU/day
• 6-12 months: 150,000 IU oral once, then 400 IU/day
• 12 months: 300,000 IU oral (or 600,000 IU in 2 divided doses), then 400-1,000 IU/day

Monitoring Treatment:

• Calcium: Monitor weekly initially (risk of hypercalcaemia/hypercalciuria)
• Phosphate: Should normalize within 2-4 weeks
• ALP: Peaks at 2-4 weeks, normalizes by 12-24 weeks
• 25(OH)D: Check at 3 months; target 75 nmol/L
• Radiographs: Healing visible at 4-6 weeks; complete by 6-12 months [14]

Calcium Supplementation

Indications:

• Severe hypocalcaemia (ionized Ca < 1.0 mmol/L)
• Symptomatic hypocalcaemia (seizures, tetany)
• Dietary calcium intake < 500 mg/day
• Concurrent malabsorption

Dosing:

• Oral calcium: 30-75 mg/kg/day elemental calcium (divided doses)
• IV calcium gluconate (10%): 0.5-1.0 mL/kg over 10 minutes (emergency), then continuous infusion

Calcium Sources:

• Calcium carbonate: 40% elemental calcium (best absorbed with food)
• Calcium citrate: 21% elemental calcium (better in achlorhydria)

Maintenance Therapy

After Healing (Lifelong if Risk Factors Persist):

• Infants (0-12 months): 400 IU/day [7]
• Children (1-18 years): 600-1,000 IU/day
• Higher doses: Dark skin, limited sun exposure, northern latitudes, malabsorption

Dietary Optimization:

• Vitamin D-rich foods: Oily fish (salmon, mackerel), egg yolks, fortified milk/cereals
• Calcium-rich foods: Dairy products, fortified plant milks, green leafy vegetables

Prevention Strategies

Universal Supplementation: [7]

• All infants: 400 IU/day from birth to 12 months
• Exclusively/partially breastfed: Continue throughout breastfeeding
• Formula-fed: If < 1 L/day formula intake

High-Risk Groups (Higher Doses):

• Dark skin: 800-1,000 IU/day
• Limited sun exposure: 800-1,000 IU/day
• Malabsorption disorders: 2,000-4,000 IU/day (monitor levels)

Genetic/Metabolic Rickets

X-Linked Hypophosphataemic Rickets (XLH)

Medical Management: [15]

• Oral phosphate: 20-60 mg/kg/day elemental phosphate (divided 4-5× daily)
• Active vitamin D (calcitriol): 20-60 ng/kg/day (divided doses)
• Monitoring: Risk of nephrocalcinosis (renal ultrasound annually), tertiary hyperparathyroidism

Novel Therapy:

• Burosumab: Monoclonal antibody against FGF23 (approved for XLH)
  • "Dose: 0.8 mg/kg SC every 2 weeks (children); 1 mg/kg every 4 weeks (adults)"
  • Normalizes phosphate, improves skeletal outcomes [16]
  • Avoids nephrocalcinosis risk of conventional therapy

Surgical Management:

• Guided growth (tension band plates, eight-plates) for angular deformities
• Osteotomy for severe deformities (after skeletal maturity preferred)

Vitamin D-Dependent Rickets Type 1 (VDDR1)

• Calcitriol (1,25(OH)₂D): 1-2 mcg/day
• Calcium supplementation: Often required initially
• Lifelong therapy: Genetic defect in 1α-hydroxylase

Vitamin D-Dependent Rickets Type 2 (VDDR2)

• Very high-dose calcitriol: 5-20 mcg/day (or higher)
• IV calcium: If oral therapy fails (severe VDR resistance)
• Alopecia: Does not respond to treatment (hallmark feature)

Hereditary Hypophosphataemic Rickets with Hypercalciuria (HHRH)

• Oral phosphate alone: 1-3 g/day (divided doses)
• NO calcitriol: Risk of hypercalciuria, nephrocalcinosis
• Hydration: Maintain high fluid intake

Surgical Management

Indications for Orthopaedic Intervention

Relative Indications:

• Persistent deformity after 2-3 years of medical therapy
• Intercondylar/intermalleolar distance 10 cm despite treatment
• Progressive deformity
• Functional impairment (gait disturbance, pain)

Timing:

• Preferred: After biochemical normalization and radiological healing
• Growth modulation (guided growth): Age 2-12 years (open growth plates)
• Corrective osteotomy: If growth plates closed or severe deformity

Surgical Options

Guided Growth (Hemiepiphysiodesis):

• Tension band plates or eight-plates: Applied to convex side of deformity
• Mechanism: Suppresses growth on one side → gradual correction
• Advantages: Minimally invasive, reversible, gradual correction
• Disadvantages: Requires open growth plates; risk of rebound deformity

Corrective Osteotomy:

• Indications: Severe deformity (20° angulation), closed growth plates
• Techniques: Closing wedge, opening wedge, dome osteotomy
• Fixation: Plates, external fixators (Ilizarov, Taylor Spatial Frame)
• Advantages: Immediate correction
• Disadvantages: Invasive, longer recovery, complications (infection, nonunion)

Management of Complications

Hypocalcaemic Seizures (Emergency)

1. IV calcium gluconate (10%): 0.5-1.0 mL/kg (max 20 mL) over 10 minutes
2. Continuous infusion: 50 mg/kg/day elemental calcium (if seizures recur)
3. Monitor: ECG (risk of bradycardia if infused rapidly), serum calcium
4. Anticonvulsants: Usually not required once calcium corrected

Dilated Cardiomyopathy

• Urgent cardiology referral
• Heart failure management: Diuretics, ACE inhibitors, beta-blockers
• Calcium/vitamin D repletion: May reverse cardiomyopathy [11]
• Monitor: Echocardiography, ECG (QT interval)

Respiratory Failure

• Oxygen therapy: Maintain SpO₂ 94%
• Ventilatory support: CPAP/BiPAP or intubation if severe
• Treat underlying cause: Calcium/vitamin D, treat pneumonia

---

8. Complications

Skeletal Complications

Permanent Deformity

• Genu varum/valgum: May persist despite medical therapy if delayed treatment
• Short stature: Growth plate damage → reduced final height
• Coxa vara: Hip deformity → gait abnormalities
• Spinal deformities: Scoliosis, kyphosis

Fractures

• Pathological fractures: Through weakened bone
• Stress fractures: Chronic insufficiency fractures
• Greenstick fractures: Incomplete fractures in soft bone

Dental Problems

• Enamel hypoplasia: Permanent; increased caries risk
• Delayed eruption: Can persist
• Malocclusion: From jaw deformities

Neurological Complications

Acute Hypocalcaemia

• Seizures: Generalized tonic-clonic; recurrent if calcium not corrected
• Tetany: Painful muscle spasms
• Laryngospasm: Life-threatening airway obstruction
• Apnoea: Especially in neonates

Chronic

• Developmental delay: Motor milestones (usually catch up with treatment)
• Cognitive impairment: Rare; if severe hypocalcaemia/hypoxia

Cardiac Complications [11]

• Dilated cardiomyopathy: Can be reversible with treatment
• Heart failure: Acute decompensation; requires intensive care
• Arrhythmias: Prolonged QT → torsades de pointes

Respiratory Complications

• Recurrent pneumonia: Impaired immunity, chest wall deformity [12]
• Respiratory failure: Muscle weakness, restrictive lung disease
• Chronic respiratory insufficiency: From severe chest wall deformity

Renal Complications (Iatrogenic)

• Nephrocalcinosis: Excess calcium/vitamin D; monitoring essential
• Nephrolithiasis: Calcium stones
• Renal impairment: From chronic nephrocalcinosis

Psychosocial Impact

• Delayed walking: Social isolation
• Visible deformity: Stigma, bullying
• Chronic pain: Quality of life impact
• Frequent medical visits: School absence, family stress

---

9. Prognosis \u0026 Outcomes

Biochemical Recovery [14]

Radiological Healing [14]

• First signs: 2-4 weeks (metaphyseal sclerosis, sharpening of provisional zone)
• Visible improvement: 6-12 weeks (reduction in cupping/fraying)
• Complete healing: 6-12 months (restoration of normal metaphyseal contour)
• Remodeling of deformities: 1-3 years (depends on age, severity)

Clinical Outcomes

Skeletal Outcomes (Nutritional Rickets, Early Treatment)

• Biochemical cure: 100% with adequate treatment
• Radiological healing: 95-100% by 6 months
• Resolution of deformities: 60-80% with medical therapy alone (age-dependent)
• Need for surgery: 10-20% (severe or late-presenting cases)
• Final height: Usually normal if treated before age 2-3 years

Prognostic Factors for Skeletal Recovery

Favourable:

• Age < 2 years at diagnosis
• Mild-moderate deformity (intercondylar distance < 8 cm)
• Prompt treatment initiation
• Good compliance

Unfavourable:

• Age 3 years at diagnosis
• Severe deformity (intercondylar distance 10 cm)
• Delayed treatment (6 months after diagnosis)
• Genetic/metabolic rickets (requires ongoing therapy)

Growth Outcomes

• Catch-up growth: 6-18 months after treatment initiation
• Final height: Normal if early treatment; 5-10 cm deficit if late treatment
• Growth velocity: Accelerated during first year of treatment

Neurodevelopmental Outcomes

• Motor milestones: Catch up within 6-12 months (if no hypoxic injury)
• Cognitive development: Usually normal (no direct effect of rickets)
• Muscle strength: Normalizes with vitamin D repletion

Cardiac Outcomes

• Cardiomyopathy: Reversible in majority if treated early [11]
• LV function: Improves within 3-6 months of vitamin D repletion
• Long-term: Normal cardiac function expected

Genetic Rickets Outcomes

X-Linked Hypophosphataemic Rickets (XLH)

• Lifelong therapy required: Oral phosphate ± calcitriol or burosumab
• Linear growth: Remains below genetic potential despite treatment
• Skeletal deformities: Progress without treatment; stabilize with therapy
• Dental abscesses: Recurrent problem
• Bone pain, osteoarthritis: Common in adulthood
• Quality of life: Significantly impacted; burosumab may improve outcomes [16]

VDDR Types 1 \u0026 2

• Lifelong calcitriol required: VDDR1 responds well; VDDR2 variable
• Growth: Normal with adequate treatment
• Skeletal health: Maintained with compliance

Recurrence Risk

Nutritional Rickets:

• High risk if predisposing factors not addressed (e.g., no maintenance vitamin D)
• Prevention: Ongoing supplementation, dietary optimization, sun exposure

Genetic Rickets:

• Inheritance patterns: XLH (X-linked dominant, 50% risk), VDDR1/2 (autosomal recessive, 25% risk)
• Genetic counseling: Recommended for affected families

Long-Term Sequelae (Untreated/Late-Treated)

• Permanent skeletal deformity: Requires surgical correction
• Short stature: Final height 10-20 cm below genetic potential
• Osteoarthritis: Early onset (hip, knee) from joint incongruity
• Chronic pain: Bone and joint pain
• Reduced mobility: Gait abnormalities, disability

Mortality

• Nutritional rickets: Rare in modern era; deaths from hypocalcaemic seizures, cardiomyopathy, respiratory failure
• Genetic rickets: Normal life expectancy with treatment

---

10. Evidence \u0026 Guidelines

Key Guidelines

Global Consensus (2016) [1]

Munns CF, et al. Global Consensus Recommendations on Prevention and Management of Nutritional Rickets. JCEM. 2016;101(2):394-415. PMID: 26745253

• Prevention: 400 IU/day vitamin D for all infants
• Treatment: Age-based vitamin D dosing (see Management section)
• Monitoring: Biochemical and radiological parameters
• 25(OH)D targets: 50 nmol/L (20 ng/mL) to prevent rickets

UK Guidelines

RCPCH Vitamin D Supplementation Guidance:

• All infants from birth: 400 IU/day (regardless of feeding method)
• High-risk groups: 800-1,000 IU/day

NICE Guidance (PH56): Vitamin D: supplement use in specific population groups

• At-risk groups: Pregnant/breastfeeding women, infants/children, dark skin, limited sun exposure
• Dose: 400 IU/day (infants), 400 IU/day (children 1-4 years)

Indian Academy of Pediatrics (2021) [17]

Gupta P, et al. Revised Guidelines on Prevention and Treatment of Vitamin D Deficiency. Indian Pediatr. 2022;59(1):142-158. PMID: 34969941

• Prevention: 400 IU/day (all infants); 600 IU/day (1-18 years)
• Treatment: Higher doses for deficiency (2,000-6,000 IU/day × 6-8 weeks)
• High-risk: Dark skin, limited sun exposure, malabsorption

European Society for Paediatric Endocrinology (2022) [4,5]

Haffner D, et al. Rickets Guidance. Pediatr Nephrol. 2022;37(9):1887-1903, 1905-1935. PMID: 34910242, 35352187

• Diagnostic workup: Comprehensive biochemical, radiological, genetic evaluation
• Management algorithms: Specific to rickets type
• Monitoring protocols: Biochemistry, radiology, adverse effects

Evidence Quality Summary

Prevention [7,18]

• High-quality evidence: Vitamin D supplementation prevents rickets in at-risk infants
• Cochrane Review (2020): Vitamin D supplementation reduces rickets risk (RR 0.07, 95% CI 0.02-0.22) [7]
• Dose-response: 400 IU/day effective; higher doses for high-risk groups

Treatment [14,18]

• Moderate-quality evidence: High-dose vitamin D heals nutritional rickets
• Optimal dosing: 2,000-6,000 IU/day × 12 weeks effective; single high-dose (stoss) also effective but safety concerns
• Calcium co-supplementation: Beneficial if dietary intake low

Burosumab for XLH [16]

• High-quality evidence: RCTs demonstrate superiority over conventional therapy
• Outcomes: Improved serum phosphate, reduced skeletal deformity, better quality of life
• Approved: FDA, EMA for XLH (pediatric and adult)

Controversial Areas

Single High-Dose (Stoss) Therapy

• Pro: Single dose improves compliance, rapid repletion
• Con: Risk of hypercalcaemia/hypercalciuria; lack of long-term safety data
• Current stance: Avoided in infants < 3 months; use with caution, close monitoring [1]

Optimal 25(OH)D Target

• Debate: 50 nmol/L vs. 75 nmol/L
• Rickets prevention: 30 nmol/L likely sufficient [13]
• Bone health optimization: 50-75 nmol/L recommended by most societies

Universal vs. Targeted Supplementation

• Universal (all children): Simplicity, ensures coverage, population-level impact
• Targeted (high-risk only): Cost-effective, reduces medicalization
• Trend: Shift toward universal in many countries due to re-emergence of rickets

---

11. Patient / Layperson Explanation

What is Rickets?

Rickets is a condition where a child's bones become soft and weak because they don't have enough vitamin D, calcium, or phosphate. These nutrients are essential for building strong, healthy bones. When children don't get enough, their bones can't harden properly, leading to bending and deformities, especially in the legs.

What Causes Rickets?

The most common cause is not getting enough vitamin D. Our bodies make vitamin D when sunlight hits our skin, but we also get some from food. Rickets can happen when:

• Not enough sunlight: Living in areas with less sunshine, staying indoors a lot, or covering skin with clothing
• Dark skin: Melanin (which makes skin darker) reduces vitamin D production
• Breastfeeding without vitamin D drops: Breast milk is wonderful but doesn't have much vitamin D
• Poor diet: Not eating foods rich in vitamin D or calcium
• Health problems: Some conditions make it hard for the body to absorb vitamin D

Less commonly, rickets can be caused by genetic conditions that run in families.

Signs Your Child Might Have Rickets

• Delayed sitting, crawling, or walking: Weak bones and muscles make movement harder
• Bowed legs or knock knees: Soft bones bend under the child's weight
• Bumps on the chest: Feels like beads along the ribs (called "rachitic rosary")
• Soft spot on the head stays open longer: The skull bones stay soft
• Being cranky or having seizures: If calcium levels get very low (rare but serious)

How is Rickets Diagnosed?

The doctor will:

1. Examine your child: Look for bone changes, measure leg angles
2. Blood tests: Check vitamin D, calcium, and phosphate levels
3. X-rays: Show if the bones are developing properly

How is Rickets Treated?

For vitamin D deficiency rickets (most common):

1. Vitamin D drops or tablets: Your child will take vitamin D supplements daily for several weeks. The dose depends on their age:

   • Babies: Usually 1,000-2,000 units per day
   • Older children: 3,000-6,000 units per day

2. Calcium supplements: Sometimes needed if your child doesn't get enough calcium from food

3. Maintenance vitamins: After the rickets heals, your child will continue taking a lower dose (400-600 units per day) to prevent it from coming back

How long does treatment take?

• Blood tests improve in 2-4 weeks
• X-rays show healing in 6-12 weeks
• Bone deformities may take 1-2 years to straighten out

Will my child need surgery? Most children's bones straighten naturally with vitamin D treatment. Surgery is rarely needed, only if:

• The bowing is very severe
• The bones don't straighten after 2-3 years of treatment

Can Rickets Be Prevented?

Yes! Rickets is preventable. Here's how:

1. Vitamin D supplements: Give your baby vitamin D drops (400 units daily) starting from birth, especially if:

   • Breastfeeding (breast milk is low in vitamin D)
   • Dark skin
   • Living in areas with limited sunshine
   • Not drinking at least 1 liter of fortified formula daily

2. Safe sun exposure:

   • 10-15 minutes of sunlight on arms and legs, 2-3 times per week (without sunscreen)
   • Important: Balance sun exposure with skin cancer prevention; never let infants sunburn

3. Vitamin D-rich foods:

   • Oily fish (salmon, mackerel)
   • Egg yolks
   • Fortified milk, cereals, orange juice

4. Calcium-rich foods:

   • Milk, cheese, yogurt
   • Fortified plant milks (soy, almond)
   • Leafy green vegetables

What Happens If Rickets Isn't Treated?

Without treatment, rickets can cause:

• Permanent bowed legs or knock knees: May require surgery later
• Short height: Growth plates don't work properly
• Seizures: From very low calcium (medical emergency)
• Heart problems: In severe cases (very rare)
• Dental problems: Weak teeth, cavities

The good news: If treated early, rickets heals completely and your child will grow up with healthy, strong bones.

Questions to Ask Your Doctor

1. What dose of vitamin D should my child take?
2. How long will my child need treatment?
3. How often do we need follow-up appointments?
4. What foods should I give my child to help their bones?
5. Will my child's legs straighten on their own, or might they need surgery?
6. Should my other children be checked or take vitamin D supplements?

Key Takeaway

Rickets is serious but highly treatable and preventable. With vitamin D supplements and proper nutrition, your child's bones will heal, and they can grow up healthy and strong. The key is starting treatment early and continuing prevention to stop it from coming back.

---

12. References

1. Munns CF, Shaw N, Kiely M, et al. Global Consensus Recommendations on Prevention and Management of Nutritional Rickets. J Clin Endocrinol Metab. 2016;101(2):394-415. doi:10.1210/jc.2015-2175. PMID: 26745253

2. Carpenter TO, Shaw NJ, Portale AA, Ettenger RB, Mallet E, Endres W. Rickets. Nat Rev Dis Primers. 2017;3:17101. doi:10.1038/nrdp.2017.101. PMID: 29265106

3. Miller WL, Levine MA. Rickets, Vitamin D, and Ca/P Metabolism. Horm Res Paediatr. 2022;95(6):579-595. doi:10.1159/000526209. PMID: 36446330

4. Haffner D, Emma F, Eastwood DM, et al. Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat Rev Nephrol. 2019;15(7):435-455. doi:10.1038/s41581-019-0152-5. PMID: 31068690

5. Haffner D, Schnabel D, Stöhr W, Leifheit-Nestler M. Rickets guidance: part I-diagnostic workup. Pediatr Nephrol. 2022;37(9):1887-1903. doi:10.1007/s00467-021-05326-5. PMID: 34910242

6. Haffner D, Schnabel D, Stöhr W, Leifheit-Nestler M. Rickets guidance: part II-management. Pediatr Nephrol. 2022;37(9):1905-1935. doi:10.1007/s00467-022-05517-8. PMID: 35352187

7. Tan ML, Abrams SA, Osborn DA. Vitamin D supplementation for term breastfed infants to prevent vitamin D deficiency and improve bone health. Cochrane Database Syst Rev. 2020;12(12):CD013046. doi:10.1002/14651858.CD013046.pub2. PMID: 33305822

8. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(7):1911-1930. doi:10.1210/jc.2011-0385. PMID: 21646368

9. Lips P, Eekhoff M, van Schoor N, et al. The effect of vitamin D on bone and osteoporosis. Best Pract Res Clin Endocrinol Metab. 2011;25(4):585-591. doi:10.1016/j.beem.2011.05.002. PMID: 21872800

10. Harvey NC, Cooper C, Harvey NC, et al. Optimisation of vitamin D status in global populations. Proc Nutr Soc. 2024;83(2):188-197. doi:10.1017/S0029665124000084. PMID: 38836946

11. Uysal S, Kalayci AG, Baysal K. Cardiac functions in children with vitamin D deficiency rickets. Pediatr Cardiol. 1999;20(4):283-286. doi:10.1007/s002469900464. PMID: 10368529

12. Uday S, Högler W. Nutritional rickets & osteomalacia: A practical approach to management. Indian J Med Res. 2020;152(4):356-367. doi:10.4103/ijmr.IJMR_1961_19. PMID: 33380700

13. Rios-Leyvraz M, Yao P, Tam E, et al. Serum 25-hydroxyvitamin D threshold and risk of rickets in young children: a systematic review and individual participant data meta-analysis to inform the development of dietary requirements for vitamin D. Eur J Nutr. 2024;63(3):673-691. doi:10.1007/s00394-023-03297-3. PMID: 38280944

14. Wu F, Juonala M, Pahkala K, et al. Vitamin D supplementation for improving bone density in vitamin D-deficient children and adolescents: systematic review and individual participant data meta-analysis of randomized controlled trials. Am J Clin Nutr. 2023;118(5):975-986. doi:10.1016/j.ajcnut.2023.08.019. PMID: 37661104

15. Haffner D, Emma F, Eastwood DM, et al. Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat Rev Nephrol. 2019;15(7):435-455. doi:10.1038/s41581-019-0152-5. PMID: 31068690

16. Carpenter TO, Whyte MP, Imel EA, et al. Burosumab Therapy in Children with X-Linked Hypophosphatemia. N Engl J Med. 2018;378(21):1987-1998. doi:10.1056/NEJMoa1714641. PMID: 29791829

17. Gupta P, Dabas A, Seth A, et al. Indian Academy of Pediatrics Revised (2021) Guidelines on Prevention and Treatment of Vitamin D Deficiency and Rickets. Indian Pediatr. 2022;59(1):142-158. PMID: 34969941

18. Chibuzor MT, Ekwochi U, Esangbedo DO. Vitamin D, calcium or a combination of vitamin D and calcium for the treatment of nutritional rickets in children. Cochrane Database Syst Rev. 2020;4(4):CD012581. doi:10.1002/14651858.CD012581.pub2. PMID: 32303107